Company Analysis
Sign in

Pliant Therapeutics, Inc. (PLRX)

Nasdaq: PLRX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.7
◀ Past 4.4● Present 5.4▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Pliant Therapeutics, Inc.’s names, not what it holds today.

Patents granted
15
14 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 3 in 2023
Applications published
32
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Organic fine chemistry5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Pliant Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
31 published
Pliant Therapeutics, Inc. its own name
US, as the owner printed on each patent
15 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 2025RE50,554Amino acid compounds and methods of usePliant Therapeutics, Inc.
Aug 19, 202512,390,463Dosage forms and regimens for amino acid compoundsPharmaceuticalsPliant Therapeutics, Inc.
Nov 5, 202412,134,642Antibodies binding to α7β1 integrin antibodies and compositions thereofPharmaceuticalsPliant Therapeutics, Inc.
Jun 25, 202412,018,025Integrin inhibitor and uses thereofOrganic fine chemistryPliant Therapeutics, Inc.
Apr 9, 202411,952,376Substituted amino acids as integrin inhibitorsPharmaceuticalsPliant Therapeutics, Inc.
Jan 2, 202411,858,931Amino acid compounds with unbranched linkers and methods of useOrganic fine chemistryPliant Therapeutics, Inc.
Jun 13, 202311,673,887N-acyl amino acid compounds and methods of useOrganic fine chemistryPliant Therapeutics, Inc.
Apr 25, 202311,634,418Amino acid compounds and methods of usePharmaceuticalsPliant Therapeutics, Inc.
Jan 24, 202311,560,376Amino acid compounds and methods of useOrganic fine chemistryPliant Therapeutics, Inc.
Aug 23, 202211,419,869Dosage forms and regimens for amino acid compoundsPharmaceuticalsPliant Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 10, 20252025/0223288AMINO ACID COMPOUNDS AND METHODS OF USEOrganic fine chemistryPliant Therapeutics, Inc.
Jun 19, 20252025/0197393INTEGRIN INHIBITOR AND USES THEREOFPharmaceuticalsPliant Therapeutics, Inc.
Apr 17, 20252025/0120975INTEGRIN INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITISPharmaceuticalsPliant Therapeutics, Inc.
Jan 23, 20252025/0026819METHODS OF TREATMENT COMPRISING ANTIBODIES BINDING TO ALPHA7BETA1 INTEGRIN ANTIBODIESPharmaceuticalsPliant Therapeutics, Inc.
Nov 28, 20242024/0391914INTEGRIN INHIBITOR AND USES THEREOFOrganic fine chemistryPliant Therapeutics, Inc.
Oct 24, 20242024/0350494THERAPEUTIC MODULATION OF INTEGRINSPharmaceuticalsPliant Therapeutics, Inc.
Sep 5, 20242024/0294520AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USEOrganic fine chemistryPliant Therapeutics, Inc.
Aug 15, 20242024/0270742SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORSPharmaceuticalsPliant Therapeutics, Inc.
Jul 25, 20242024/0245682ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOFPharmaceuticalsPliant Therapeutics, Inc.
Apr 18, 20242024/0122930INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTSPharmaceuticalsPliant Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PLRX · research, not advice